Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 5/20 | 0.39 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | KDM1A | O60341 | 4/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23951733 | 1.00 | GBA1 (0.50) | GBA1SLC18A3SIGMAR1MEN1KMT2A | |
| SCHEMBL15250705 | 1.00 | GBA1 (0.50) | GBA1SLC18A3SIGMAR1MEN1KMT2A | |
| SCHEMBL5521949 | 1.00 | GBA1 (0.50) | GBA1SLC18A3SIGMAR1MEN1KMT2A | |
| SCHEMBL8222209 | 0.83 | SLC18A3 (0.52) | GBA1SLC18A3SIGMAR1MEN1KMT2A | |
| Bromide SCHEMBL28484405 | 0.81 | SLC18A3 (0.50) | GBA1SLC18A3SIGMAR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL28486863 | 0.81 | SLC18A3 (0.50) | GBA1SLC18A3SIGMAR1MEN1KMT2A | |
| SCHEMBL28875477 | 0.77 | POLB (0.40) | GBA1MEN1KMT2A | |
| Trimethylammonium SCHEMBL28490265 | 0.75 | SLC18A3 (0.45) | GBA1SLC18A3SIGMAR1MEN1KMT2A | |
| SCHEMBL19270305 | 0.74 | SMN1; SMN2 (0.40) | GBA1SLC18A3SIGMAR1MEN1KMT2A | |
| SCHEMBL12371293 | 0.74 | GBA1 (0.57) | GBA1SLC18A3SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398774-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Corporation (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | claimed |
| WO-2010083283-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2010-07-22 | — | — | WO | claimed |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | INCYTE HOLDINGS CORPORATION (US) | 2025-03-11 | — | — | US | disclosed |
| EP-4501410-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Holdings Corporation (US) | 2025-02-05 | — | — | EP | disclosed |
| CN-119306753-A | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3272738-B1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE HOLDINGS CORP (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-108395433-B | Methods for preparing JAK inhibitors and related intermediate compounds | 因西特控股公司 | 2024-10-22 | — | — | CN | disclosed |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | INCYTE HOLDINGS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | INCYTE HOLDINGS CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
| WO-2005080298-A1 | CATALYTIC ASYMMETRIC SYNTHESIS OF OPTICALLY ACTIVE α-HALO-CARBONYL COMPOUNDS | CHEMINOVA A/S (DK) | 2005-09-01 | — | — | WO | disclosed |
| EP-0004748-B1 | ELECTROSTATOGRAPHIC DEVELOPER MIXTURE AND IMAGING PROCESS | XEROX CORPORATION (US) | 1984-03-14 | — | — | EP | disclosed |
| US-4395471-A | BUTYL METHACRYLATE-STYRENE COPOLYMER AND A COPPER PHTHALOCYANINE, AND A AZOBENZIDENE | XEROX CORPORATION (US) | 1983-07-26 | — | — | US | disclosed |
| EP-0046398-A2 | Electrostatographic developer composition | XEROX CORPORATION (US) | 1982-02-24 | — | — | EP | disclosed |
| US-4312932-A | RESIN PARTICLES CONTAINING UP TO FOUR PIGMENTS AND SINGLE CARRIER | XEROX CORPORATION (US) | 1982-01-26 | — | — | US | disclosed |
| US-4172721-A | USING MONLAYER OF PARTICLES COMPRISING A RESIN CARRIER CONTAINING COLOR-PHOTOSENSITIVE MATERIAL AND A SOLID-FORM DYE MATERIAL | XEROX CORPORATION (US) | 1979-10-30 | — | — | US | disclosed |
| EP-0004748-A2 | Electrostatographic developer mixture and imaging process | XEROX CORPORATION (US) | 1979-10-17 | — | — | EP | disclosed |
| US-4052207-A | XEROGRAPHY, YELLOW MONOAZO DYE | XEROX CORPORATION (US) | 1977-10-04 | — | — | US | disclosed |
| US-4035310-A | STYRENE-VINYL, STYRENE-ACRYLATE COPOLYMERS | XEROX CORPORATION (US) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247030-B2 | Process for preparing compositions comprising an enantiomeric excess of a substituted pyrrolo[2,3-d]pyrimidine | DPYD, TYMS, TYMP | GBA1 3329/4885SLC18A3 3633/4885SIGMAR1 4082/4885 |
| US-10975085-B2 | Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III | JAK1, JAK3, JAK2 | GBA1 4055/4885SLC18A3 4881/4885SIGMAR1 2072/4885 |
| US-20210253584-A1 | Processes for Preparing Jak Inhibitors and Related Intermediate Compounds | JAK3, JAK1, JAK2 | GBA1 4400/4885SLC18A3 4878/4885SIGMAR1 3460/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | GBA1 4400/4885SLC18A3 4878/4885SIGMAR1 3460/4885 |
| US-20250340559-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | GBA1 4400/4885SLC18A3 4878/4885SIGMAR1 3460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.